مقالات انگلیسی مقالات علمی

Management of Dyslipidemia/Lipids ADA 2015

lipid
نوشته شده توسط دکتر افشین عشقی

 

Management of Dyslipidemia/Lipids 
Treatment initiation and initial dose driven by risk status—not LDL-C level
Age Risk Factors Statin Intensity Monitoring
<40 ۰
CVD risk factors
Overt CVD
N/A
Moderate or high
High
Annually or as needed to check adherence
۴۰-۷۵ ۰
CVD risk factors
Overt CVD
N/A
Moderate or high
High
As needed to check adherence
>75 ۰
CVD risk factors
Overt CVD
N/A
Moderate or high
High
As needed to check adherence
Screening at diabetes diagnosis, initial medical evaluation, and/or at age 40
Every 1-2 years thereafter
CVD risk factors: LDL-C ≥۱۰۰ mg/dL (2.6 mmol/L), high blood pressure, smoking, overweight/obesity
Overt CVD: Invidivuals with prior cardiovascular events or acute coronary syndromeAt time of publication, combination therapy (statin + non-statin) for lipid lowering was not shown to provide incremental CVD benefit. Results from IMPROVE-IT1 have since shown a 2% CV risk reduction with ezetimibe/statin vs statin alone.

۱٫ Cannon CP, et al. Presented at the American Heart Association Scientific Sessions 2014; Chicago, Illinois.

درباره نویسنده

دکتر افشین عشقی

دکتر افشین عشقی کار خود را در زمینه معالجه بیماران دیابتی در سال ...

دیدگاهتان را بنویسید